Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ERICH2 divergent transcript (ERICH2-DT) is a long noncoding RNA (lncRNA) gene classified as a divergent transcript, meaning it is transcribed from the opposite DNA strand in close proximity to a protein-coding gene (in this case, ERICH2)[7]. Divergent lncRNAs are known to potentially regulate the expression of neighboring protein-coding genes through various mechanisms, including chromatin remodeling and cis-regulation. There is limited evidence to suggest that ERICH2-DT has been characterized as a direct therapeutic target, nor are there any known drugs or disease associations specifically documented for this RNA[4][7].\n\nKey clarifications:\n- ERICH2-DT is not a protein, receptor, transporter, channel, enzyme, nor a classic therapeutic target.\n- The available evidence highlights its classification as a noncoding RNA gene, with possible regulatory functions inferred from broader lncRNA biology[2][3][4][7].\n- The search results indicate limited functional or clinical annotation specifically for ERICH2-DT.\n\nIf you need structured information for classic drug targets, ERICH2-DT does not fit this category at present.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ERICH2 divergent transcript (ERICH2-DT).